Pharmacogenetics: Part II.
作者信息
Gibaldi M
机构信息
School of Pharmacy, University of Washington, Seattle 98915.
出版信息
Ann Pharmacother. 1992 Feb;26(2):255-61. doi: 10.1177/106002809202600223.
PMID:1554942
Abstract
摘要
相似文献
1
Pharmacogenetics: Part II.药物遗传学：第二部分。
Ann Pharmacother. 1992 Feb;26(2):255-61. doi: 10.1177/106002809202600223.
2
Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
Pharmacogenetics. 1994 Jun;4(3):159-61. doi: 10.1097/00008571-199406000-00007.
3
[Role of pharmacogenetics in psychopharmacotherapy].[药物遗传学在精神药物治疗中的作用]
Encephale. 1991 May-Jun;17 Spec No 1:123-5.
4
Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.对与异喹胍/司巴丁遗传多态性相关的CYP2D6(A)和CYP2D6(B)无效等位基因的简单聚合酶链反应分析解读
Pharmacogenetics. 1994 Jun;4(3):154-8. doi: 10.1097/00008571-199406000-00006.
5
6
7
Variants of human microsomal enzymes.人类微粒体酶的变体。
Biochem Soc Trans. 1983 Aug;11(4):459-60. doi: 10.1042/bst0110459.
8
Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations.
Clin Pharmacol Ther. 1994 Apr;55(4):412-7. doi: 10.1038/clpt.1994.50.
9
The pharmacogenetics of codeine hypoalgesia.可待因镇痛不足的药物遗传学
Pharmacogenetics. 1995 Dec;5(6):335-46. doi: 10.1097/00008571-199512000-00001.
10
Debrisoquine hydroxylation in a Polish population.
Eur J Clin Pharmacol. 1995;47(6):503-5. doi: 10.1007/BF00193702.
Zotero 插件